Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
ACTIVE_NOT_RECRUITING
Status
Conditions
- Hydronephrosis
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
- Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant
- Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
- Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant
- Renal Pelvis Urothelial Carcinoma
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage II Renal Pelvis Cancer AJCC v7
- Stage II Ureter Cancer AJCC v7
- Stage II Urethral Cancer AJCC v7
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Renal Pelvis Cancer AJCC v7
- Stage III Ureter Cancer AJCC v7
- Stage III Urethral Cancer AJCC v7
- Stage IV Renal Pelvis Cancer AJCC v7
- Stage IV Ureter Cancer AJCC v7
- Stage IV Urethral Cancer AJCC v7
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma
Interventions
- BIOLOGICAL: Durvalumab
- PROCEDURE: Therapeutic Conventional Surgery
- BIOLOGICAL: Tremelimumab
Sponsor
M.D. Anderson Cancer Center
Collaborators